4 Healthcare Stock Stories For a Monday Investment Checkup

GlaxoSmithKline (NYSE:GSK): Closing price $52.65

On Monday, Glaxo said that it has ceased using all the travel agencies which the Chinese police have accused of channeling bribes so as to illegally push sales, and inflate the price of its medicines in that country. Earlier in the day, Chinese police had said that four senior Chinese executives from GlaxoSmithKline had been detained as part of the inquiry. In a company statement, it was said that “GSK shares the desire of the Chinese authorities to root out corruption. These allegations are shameful and we regret this has occurred. We are taking a number of immediate actions.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK

Actavis, Inc. (NYSE:ACT): Closing price $125.13

Activis announced Monday that it has received clearance from the FDA on its abbreviated new drug application for Lamotrigine Orally Disintegrating Tablets, 25 mg, 50 mg, 100 mg and 200 mg, which is the a generic equivalent to GlaxoSmithKline’s Lamictal ODT. Actavis intends to debut the product at once. Being a “first applicant” to submit a substantially complete application, Actavis might be eligible for 180 days of generic market exclusivity.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACT

AstraZeneca Group (NYSE:AZN): Closing price $49.49

On Monday, AstraZeneca reported that Chief Financial Officer and Executive Director Simon Lowth will exit the company at the end of October, following the posting of third quarter results. Lowth has been named CFO for the BG Group PLC and will assume his new position in November. Also, he will keep his responsibilities as CFO, and will continue to be a member of the AstraZeneca Board until he leaves the firm. Meanwhile, a search for Lowth’s successor is ongoing.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AZN

Mylan Inc. (NASDAQ:MYL): Closing price $32.10

Mylan reports that its subsidiary Mylan Pharmaceuticals Inc. has introduced Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg. Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg, represent the generic version of Abbott’s Trilipix Capsules, which are indicated as an adjunct to diet combined with a statin to lower triglyceride and increase high-density lipoprotein cholesterol in patients having mixed dyslipidemia and CHD or a CHD risk equivalent, who are on optimal statin therapy through which to achieve their low-density lipoprotein cholesterol goal. Mylan received final clearance from the FDA for its Abbreviated New Drug Application for the product.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MYL

Don’t Miss: GlaxoSmithKline’s Bribery Allegations in China Keep Growing.